The PLOS ONE Staff (2014) Correction: The ACTN3 R577X Polymorphism across Three Groups of Elite Male European Athletes. PLoS ONE 9(3): e93165. doi: 10.1371/journal.pone.0093165 ; The ACTN3 R577X polymorphism (rs1815739) is a strong candidate to influence elite athletic performance. Yet, controversy exists in the literature owing to between-studies differences in the ethnic background and sample size of the cohorts, the latter being usually low, which makes comparisons difficult. In this case:control genetic study we determined the association between elite athletic status and the ACTN3 R577X polymorphism within three cohorts of European Caucasian men, i.e. Spanish, Polish and Russian [633 cases (278 elite endurance and 355 power athletes), and 808 non-athletic controls]. The odds ratio (OR) of a power athlete harbouring the XX versus the RR genotype compared with sedentary controls was 0.54 [95% confidence interval (CI): 0.34???0.48; P = 0.006]. We also observed that the OR of an endurance athlete having the XX versus the RR genotype compared with power athletes was 1.88 (95%CI: 1.07???3.31; P = 0.028). In endurance athletes, the OR of a ???world-class??? competitor having the XX genotype versus the RR+RX genotype was 3.74 (95%CI: 1.08???12.94; P = 0.038) compared with those of a lower (???national???) competition level. No association (P>0.1) was noted between the ACTN3 R577X polymorphism and competition level (world-class versus national-level) in power athletes. Our data provide comprehensive support for the influence of the ACTN3 R577X polymorphism on elite athletic performance.